British scientists have hailed the US approval of a new drug for schizophrenia, saying it “has the potential to change the lives of millions of people”. The “major advance” in treatment offers a completely new drug approach to treating the condition, which can cause terrifying hallucinations, delusional thoughts and social withdrawal. The US Food and Drug Administration (FDA) has approved the new drug Cobenfy, which is owned by pharmaceutical firm Bristol Myers Squibb, overnight into Friday. The FDA’s approval was based on data from two studies showing patients experienced fewer schizophrenia …